Injektionstherapie (GLP1-Rezeptor Agonisten und Insulin) bei Typ 2 Diabetes mellitus (Update 2023)-Reference-Cited by-同舟云学术

Injektionstherapie (GLP1-Rezeptor Agonisten und Insulin) bei Typ 2 Diabetes mellitus (Update 2023)

Published:2023-01 Issue:S1 Volume:135 Page:45-52
ISSN:0043-5325
Container-title:Wiener klinische Wochenschrift
language:de
Short-container-title:Wien Klin Wochenschr

Author:

Lechleitner Monika,Roden Michael,Weitgasser Raimund,Ludvik Bernhard,Fasching Peter,Hoppichler Friedrich,Kautzky-Willer Alexandra,Schernthaner Guntram,Prager Rudolf,Kaser Susanne,Wascher T. C.,

Abstract

ZusammenfassungDie vorliegende Leitlinie nimmt Bezug auf die Indikation und praktische Umsetzung der Injektionstherapie (GLP1-Rezeptor Agonisten und Insulin) bei Typ 2 Diabetes.

Funder

Medical University of Vienna

Publisher

Springer Science and Business Media LLC

Subject

General Medicine

Link

https://link.springer.com/content/pdf/10.1007/s00508-023-02171-x.pdf

Reference42 articles.

1. American Diabetes Association. Pharmacologic approaches to glycemic treatment: Standards of medical care in diabetes—2023. Diabetes Care. 2023;46(Suppl 1):S140–S57.

2. Singh S, Wright EE jr., Kwan AYM, et al. Glucagon-like peptide‑1 receptor agonists compared with basal insulins for the treatment of type 2 diabetes mellitus: a systematic review and meta-analysis. Diabetes Obes Metab. 2017;19:228–38.

3. Frias JP. Prioritising injectable therapies in the management of type 2 diabetes. Lancet Diabetes Endocrinol. 2019;7:505–8.

4. Alexopoulos A, Buse JB. Initial injectable therapy in type 2 diabetes: key considerations when chosing between glucagon-like pepetide 1 receptor agonists and insulin. Metabolism. 2019;98:104–11.

5. Abd El Aziz MS, Kahle M, Meier JJ, Nauck MA. Meta-analysis comparing clinical effects of short- or long-acting GLP-1-receptor agonists versus insulin treatment from head-to-head studies in type 2 diabetic patients. Diabetes Obes Metab. 2017;19:216–27.